| Literature DB >> 33986652 |
Mandy Roheger1,2, Hannah Liebermann-Jordanidis2, Fabian Krohm2, Anne Adams3, Elke Kalbe2.
Abstract
Background: Cognitive Training (CT) may contribute to the maintenance and even enhancement of cognitive functions in healthy older adults. However, the question who benefits most from multi-domain CTs is still highly under-investigated. Objective: The goal is to investigate prognostic factors and models for changes in cognitive test performance in healthy older adults after a multi-domain CT.Entities:
Keywords: cognition; cognitive training; memory; prediction; prognostic factors; prognostic model
Year: 2021 PMID: 33986652 PMCID: PMC8110835 DOI: 10.3389/fnhum.2021.636355
Source DB: PubMed Journal: Front Hum Neurosci ISSN: 1662-5161 Impact factor: 3.169
Figure 1PRISMA diagram showing the study selection process.
Participants' demographics and memory training characteristics.
| Akimoto et al. ( | x | Group P: 9 | Group P: 68.71 (5.96) | Group P: | Group P: 13.44 (2.40) | MMSE: | 480 | 24 sessions, 3 days a week for 8 weeks | Cognitive intervention: | x | x | ||||
| Anderson et al. ( | x | 30 | 62.30 (3.40) | 16 ♀, 14 ♂ | n.a. | WAIS: | 2,400 | 40 sessions, 5 sessions per week for 8 weeks | Auditory-based CT, | x | x | ||||
| Bellander et al. ( | x | 103 | 71.30 (4.10) | 51 ♀, 52 ♂ | 13.60 (3.60) | n.a. | 6,060 | 101 days | CT with 12 computerized tasks | x | x | ||||
| Binder et al. ( | x | 21 | 69.62 (2.85) | 13 ♀, 8 ♂ | 9.55 (1.61) | MMSE: 28.90 (0.89) | Max. 3,000 | 50 sessions, 5 sessions per week for 10 weeks | Multi-domain CT | x | x | ||||
| Fernández-Prado et al. ( | x | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | Cognitive stimulation program | x | x | ||||
| Gallen et al. ( | x | 24 | 63.10 (2.90) | 9 ♀, 15 ♂ | n.a. | IQ: 122.1 (8.3) | 2,160 | 1 group session per week over 12 weeks, 2 individual sessions per week over 12 weeks | CT (SMART) | x | x | ||||
| Kim et al. ( | x | Traditional: 24 | Traditional: 67.70 (5.40) | Traditional: 6 ♀, 18 ♂ | Traditional: 14.00 (3.30) | K-MMSE | 5,400 | 60 sessions, 5 days per week over 12 weeks | Traditional and robot-assisted multi-domain CT | x | x | x | |||
| Legault et al. ( | x | 18 | 76.00 (5.20) | 8 ♀, 10 ♂ | n.a. | MMMSE: 95.60 (3.40) | 1,152 | 24 sessions, 8 per month during Months 1-2 and 4 per month during Months 3-4 | CT (Active Mind) | x | x | x | |||
| López-Higes et al. ( | x | CI:32 | CI: 70.94 (4.16) | CI: 20 ♀, 12 ♂ | CI: 14.38 (5.88) | MMSE: | 2,700 | 3 sessions per week over 13 weeks | UMAM CT Program | x | x | ||||
| López-Higes et al. ( | x | 66, CI: 31 SCD: 35 | CI: 70.94 (4.16); SCD: 71.39 (4.96) | CI: 12 ♂, 19 ♀; SCD: 10 ♂, 25 ♀ | CI: 14.38 (5.88); SCD: 13.02 (6.05) | MMSE: CI: 28.94 (1.19); SCD: 28.45 (1.50) | 2,700 | 3 sessions per week over 13 weeks | UMAM CT Program | x | x | ||||
| Lövdén et al. ( | x | 12 | 68.90 (2.70) | 5 ♂, 7 ♀ | n.a. | n.a. | 6,060 | Up to 101 sessions | CT with 12 computerized tasks | x | x | ||||
| Mayas et al. ( | x | 15 | 68.70 (5.20) | 6 ♂, 9 ♀ | 11.90 (4.80) | MMSE: 28.9 (1.00) | 1m200 | 20 1h sessions across a period of 10-12 weeks | Video training Lumosity | x | x | ||||
| McDougall and House ( | x | 21 | 74.81 (7.85) | 11 ♂, 10 ♀ | n.a. | n.a. | n.a. | 6 weeks, participants should use it regularly | Nintendo “Brain Training” | x | x | ||||
| Miller et al. ( | x | 42 | 82.20 (4.40) | 15 ♂, 27 ♀ | 16.20 (2.20) | MMSE: 28.00 (1.50); MocA: 24.20 (3.10) | 800 | 5 days a week for 20–25 min each day for 8 weeks | Brain fitness | x | x | ||||
| Niu et al. ( | X | 16 | 69.60 (4.60) | 7 ♂, 9 ♀ | 12.40 (3.50) | MMSE: 27.70 (1.50) | 960 | 16 sessions over 6 weeks | Combined CT | x | x | ||||
| Nouchi et al. ( | x | 27 | 71.67 (3.62) | n.a. | 12.96 (2.01) | MMSE: 28.93 (1.14) | Minimum: 600 | at least 5 days per week, for a total of 6 weeks | CT game for car driving group | x | x | ||||
| Oswald et al. ( | x | 272 in total | n.a. | n.a. | n.a. | n.a. | Minimum: 3,600 | Once a week over 30 sessions | Competence-training Program | x | x | ||||
| Otsuka et al. ( | X | 14 | 82.21 (2.89) | n.a. | 11.07 (2.53) | MMSE: 27.50 (2.14) | 1,125 | Once a week for 4 times a month, for about 6 months | Atama-nodojo | x | x | x | |||
| Polito et al. ( | x | 38 | 73.80 (1.20) | 17 ♂, 21 ♀ | 7.70 (3.00) | MMSE: 28.20 (1.50), Moca: 23.20 (3.60) | 1,000 | 10 twice weekly sessions | Cognitive stimulation | x | x | x | |||
| Roheger et al. ( | x | ST: 20 | ST: 67.65 (6.86) | ST: 12 ♀ 8♂ | ST:14.80 (2.82) | DemTecT: ST: 16.60 (1.70) LT:16.76 (1.56) | 1,260 | 2 sessions over 7 weeks | NeuroVitalis CT | x | x | x | |||
| Schmiedek et al. ( | x | 101 | 71.30 (4.10) | 50 ♂, 51 ♀ | 13.60 (3.60) | n.a. | 6,060 | Up to 101 sessions | CT with 12 computerized tasks | x | x | ||||
| Shah et al. ( | x | 51 | 66.61 (4.82) | 19 ♂, 32 ♀ | 11.00 (2.00) | MMSE: 28.80 (1.18) | 2,400 | 40 sessions over 16 weeks | Cognitive Stimulation; auditory-based Brain | x | x | ||||
| Shing et al. ( | x | 101 | 71.30 (4.10) | 50 ♂, 51 ♀ | 13.60 (3.60) | n.a. | 6,060 | Up to 101 sessions | CT with 12 computerized tasks | x | x | ||||
MMSE, Mini Mental State Examination; MMMSE, Modified Mini Mental State Examination; K-MMSE, Korean version of the Mini Mental Status Examination; WAIS, Wechsler Adult Intelligence Scale; CI, Cognitively Intact, SCD, Subjective Cognitive Decline; IQ, Intelligence Quotient; MoCA, Montreal Cognitive Assessment; ST, short-term, LT, long-term; DemTect, Demenz-Detektionstest.
Total number of participants in CT group of older participants.
Detailed results of prognostic factor studies.
| Akimoto et al. ( | High gamma power change | Change score (Post-Pre) | x | x | ||||
| Anderson et al. ( | Peak variability | Change score (Post-Pre) | ↓ | ↓ | ||||
| Fernández-Prado et al. ( | Subjective health (measured with CUBRECAVI) | n.a. | ↑ | |||||
| Gallen et al. ( | 1. Baseline | Change score (Post-Pre) | 1. ↓ | |||||
| Kim et al. ( | Cortical thickness in the right inferior temporal gyrus and right subgenual cingulate region | Change score (Post-Pre) | x | ↑ | x | |||
| Legault et al. ( | 1. Age | Composite change scores (Post-Pre) | 1. ↓ All measured with composite score | 1. ↓ All measured with composite score | 1. ↓ All measured with composite score | |||
| Lövdén et al. ( | 1. Mean diffusivity | Composite change scores (Post-Pre) | x | x | ||||
| Mayas et al. ( | 1. Alertness | Change score (Post-Pre) | 1. ↓ | |||||
| McDougall and House ( | 1. Perceived cognitive function | Standardized change score (Post-Pre) | 1. ↓ | 1. ↓ Measured with vocabulary test | ||||
| Niu et al. ( | 1. RP amplitude | Standardized change score (Post-Pre) | 1. x | 1. ↑ | ||||
| Oswald et al. ( | 1. Age | Standardized change score (Post-Pre) | 1. x | 1. x | 1. x | |||
| Otsuka et al. ( | 1. Age | Change score (Post-Pre) | 1. x | 1. x | 1. x | |||
| Shah et al. ( | 1. SMC-L | n.a. | 1. ↓ | 1. ↑ | ||||
WJIII, Woodcock–Johnson III Tests of Cognitive Abilities Visual Matching sub-test; MEC, Lobo's Cognitive Mini-Exam, CUBRECAVI, Short Questionnaire on Quality of Life; TOSL, Test of Strategic Learning; PRM, Pattern Recognition Memory; ApoE4, Apoliopoprotein E 4; GDS, Geriatric Depression Scale; FAB, Frontal Assessment Battery; SMC-L, left sensorimotor cortex; FRT-L, left frontal cortex; COWAT, Controlled oral word association test; Gray Outcome domains symbolize the domains the participants were trained in the CT. x, no direction of relationship between prognostic factor and outcome was indicated, ↑ = a positive relationship was reported between the prognostic factor and the outcome, ↓ = a negative relationship was reported between the prognostic factor and the outcome,
a significant relationship (p < 0.05) was reported.
Detailed results of prognostic model studies.
| Bellander et al. ( | 1. LMX1A | Change score (Post-Pre) | 1. x | 1. x | ||||
| Schmiedek et al. ( | Age | Net effect scores | x | x | ||||
| Shing et al. ( | Age | Change score (Post-Pre) | ↓ | x | ||||
| Binder et al. ( | Baseline performance | Composite latent change score | ↓ | x | ||||
| López-Higes et al. ( | Cognitive reserve measured with digit reordering baseline performance | Change score (Post-Pre) | ↓ | |||||
| López-Higes et al. ( | Cognitive reserve measured with interference baseline performance | Change score (Post-Pre) | ↓ | |||||
| Miller et al. ( | Number of sessions (Dose) | Standardized composite change score (Post-Pre) | x | x | ||||
| Nouchi et al. ( | 1. Age | Change Score (Post-Pre) | 1. x | 1. x | 1. x | |||
| Polito et al. ( | 1. ApoE4: Carrier | Net change score | 1. ↓ measured with MMSE and MoCa | |||||
| Roheger et al. ( | 1. Age | Change scores (Post-Pre) | 1. x | 1. x | 1. x | 1. x | 1. x | 1. x |
MMSE, Mini Mental Status Examination; ApoE4, Apolipoprotein 4; MoCa, Montreal Cognitive Assessment; DemTect, Demenz-Detektionstest; ROFDR, Rey Osterrieth Figure: delayed recall; BTA, Brief Test of Attention; TMT A/B, Trial Making Test A/B; IGF-1, Insulin-like growth factor 1; VEGF, Vascular Endothelial Growth Factor; BDNF, Brain-derived neurotrophic factor; Gray Outcome domains symbolize the domains the participants were trained in the CT. x = no direction of relationship between prognostic factor in the model and outcome was indicated, ↑ = a positive relationship was reported between the prognostic factor in the model and the outcome, ↓ = a negative relationship was reported between the prognostic factor in the model and the outcome,
a significant relationship (p < 0.05) was reported.
Risk of bias assessment for prognostic factor studies.
| Akimoto et al. ( | ||||||
| Anderson et al. ( | ||||||
| Fernández-Prado et al. ( | ||||||
| Gallen et al. ( | ||||||
| Kim et al. ( | ||||||
| Legault et al. ( | ||||||
| Lövdén et al. ( | ||||||
| Mayas et al. ( | ||||||
| McDougall and House ( | ||||||
| Niu et al. ( | ||||||
| Oswald et al. ( | ||||||
| Otsuka et al. ( | ||||||
| Shah et al. ( |
Red color indicates a high risk of bias, yellow color indicates a moderate risk of bias, green color indicates a low risk of bias, assessed with the QUIPS tool (Hayden et al., .
Note that even though the quality rating for the study of Oswald et al. (.
Risk of bias assessment for prognostic model studies.
| Where appropriate data sources used, e.g. cohort, RCT? | ||||||||||
| Were all inclusions and exclusions of participants appropriate? | ||||||||||
| Were predictors defined and assessed in a similar way for all participants? | ||||||||||
| Were predictor assessments made without knowledge of outcome data? | ||||||||||
| Are all predictors available at the time the model is intended to be used? | ||||||||||
| Was the outcome determined appropriately? | ||||||||||
| Was a pre-specified or standard outcome definition used? | ||||||||||
| Were the predictors excluded from the outcome definition? | ||||||||||
| Was the outcome defined in a similar way for all participants? | ||||||||||
| Was the outcome defined without knowledge of predictors? | ||||||||||
| Time interval between outcome and predictor appropriate? | ||||||||||
| Were there a reasonable number of participants with the outcome? | ||||||||||
| Were continuous and categorical predictors handled appropriately? | ||||||||||
| Were all enrolled participants included in the analysis? | ||||||||||
| Were missing data handled appropriately? | ||||||||||
| Was selection of predictors based on univariable analysis avoided? | ||||||||||
| Were complexities in the data accounted for (e.g., censoring, control participants?) | ||||||||||
| Were relevant model performance measures evaluated? | ||||||||||
| Were over- and under-fitting accounted for? | ||||||||||
| Do predictors and weights correspond to the results from multivariable analysis? | ||||||||||
Risk of bias assessment using the “Prediction model Risk of Bias Assessment Tool (PROBAST)” (Wolff et al., .
Overview of prognostic factors/models and cognitive outcomes of the reviewed studies.
| Akimoto et al. ( | x | x | x | ||||||||||||
| Anderson et al. ( | x | x | x | ||||||||||||
| Fernández-Prado et al. ( | x | x | |||||||||||||
| Gallen et al. ( | x | x | x | ||||||||||||
| Kim et al. ( | Cortical thickness | x | x | x | |||||||||||
| Legault et al. ( | x | x | x | x | x | x | |||||||||
| Lövdén et al. ( | x | x | x | ||||||||||||
| Mayas et al. ( | x | x | |||||||||||||
| McDougall and House ( | x | x | x | x | |||||||||||
| Niu et al. ( | x | x | x | ||||||||||||
| Oswald et al. ( | x | x | x | x | x | x | |||||||||
| Otsuka et al. ( | x | x | x | x | x | x | x | ||||||||
| Shah et al. ( | x | x | x | ||||||||||||
| Bellander et al. ( | x | x | |||||||||||||
| Binder et al. ( | x | x | x | ||||||||||||
| López-Higes et al. ( | x | x | x | ||||||||||||
| López-Higes et al. ( | x | x | x | ||||||||||||
| Miller et al. ( | x | x | x | ||||||||||||
| Nouchi et al. ( | x | x | x | x | x | x | |||||||||
| Polito et al. ( | x | x | x | x | |||||||||||
| Roheger et al. ( | x | x | x | x | x | x | x | x | x | x | |||||
| Schmiedek et al. ( | x | x | x | ||||||||||||
| Shing et al. ( | x | x | x | ||||||||||||
ApoE4, Apolipoprotein E4; QoL, Quality of Life; CNV, Contingent Negativity Variation.